FULL overview
The last two years have shown what drug companies can achieve, not only in terms of the development and production of extremely innovative medicines and vaccines, but also in the delivery of tests by diagnostics makers at an unprecedented scale and speed, and to many destinations worldwide.
However, with success come new challenges as patients and other stakeholders increasingly question why healthcare continues to become more expensive, yet accessibility remains hampered by very long timeframes from the discovery to the arrival of new therapies into surgeries, clinics and pharmacies. Keeping pace with the accelerated innovation that has come to be expected will require digitalisation of even the most reluctant parts of the industry, and in particular the labs where scientists, technicians and other experts routinely handle paper and documents, work in non-standard ways and are unable to use data analytics for smarter decision making.
The Financial Times, in partnership with Dassault Systèmes brought together leading scientists, operational and technology experts from labs across the life sciences value chain - from discovery to manufacturing and quality control - to explore what it is that’s hindering digitalisation efforts, how barriers can be addressed and the benefits and returns these efforts can bring to their business, the industry and to patients.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice